Phase 3
once daily, oral
Monoamine reuptake · Abbott
Disease Pipeline Tools Obesity
Obesity
Programs, trials, and reported weight change for obesity and overweight.
Obesity pipeline
Programs by company or class, across phase, filing, approval, and a stop.
Phase 1 included.
Clear filters94 of 94 programs on this matrix
| Phase 1 | Phase 2 | Phase 3 | Filed | Approved | Discontinued | Stage n/r | |
|---|---|---|---|---|---|---|---|
| Abbott1 program | Phase 3 once daily, oral Monoamine reuptake · Abbott | ||||||
| AbbVie2 programs | Phase 1 injection Class not reported · AbbVie | Phase 2 oral and injection Amylin · AbbVie | |||||
| Aconcagua Bio, Inc1 program | Phase 1/2 oral Amylin · Aconcagua Bio, Inc | ||||||
| Alizyme1 program | Phase 1 Dosing n/r Class not reported · Alizyme | ||||||
| Altimmune1 program | Phase 2 once weekly GLP-1/glucagon · Altimmune | ||||||
| Amgen1 program | Registry, Jan 21, 2027 subcutaneous, subcutaneous GLP-1 conjugate · Amgen | ||||||
| Arrowhead1 program | Registry, Feb 2027 Dosing n/r Class not reported · Arrowhead | ||||||
| Ascletis Pharma (China) Co1 program | Phase 3 once daily, oral and injection Class not reported · Ascletis Pharma (China) Co | ||||||
| AstraZeneca5 programs | Phase 1 once daily, injection GLP-1/glucagon · AstraZeneca | Registry, Nov 18, 2026 once daily, oral Oral small molecule · AstraZeneca Phase 3 twice daily, oral and injection GLP-1 RA · AstraZeneca Phase 2/3 weekly, oral and injection Amylin · AstraZeneca Registry, May 4, 2027 weekly, oral and injection Class not reported · AstraZeneca | |||||
| Biohaven Therapeutics1 program | Phase 2 once weekly, injection Class not reported · Biohaven Therapeutics | ||||||
| Boehringer Ingelheim1 program | Registry, Dec 8, 2026 once weekly, subcutaneous GLP-1/glucagon · Boehringer Ingelheim | ||||||
| BrightGene Bio-Medical Technology Co1 program | Registry, Feb 28, 2027 once weekly, oral and injection GLP-1/GIP · BrightGene Bio-Medical Technology Co | ||||||
| Carmot Australia First Pty Ltd1 program | Phase 1 oral Class not reported · Carmot Australia First Pty Ltd | ||||||
| Carmot Therapeutics, Inc1 program | Phase 2 once daily, injection Class not reported · Carmot Therapeutics, Inc | ||||||
| Company n/r3 programs | Phase 3 once weekly, injection GLP-1 RA · Company n/r Phase 2/3 injection Class not reported · Company n/r | Stage n/r once weekly, injection GLP-1 RA · Company n/r | |||||
| Corbus Pharmaceuticals1 program | Phase 1 Dosing n/r Class not reported · Corbus Pharmaceuticals | ||||||
| CSPC Baike (Shandong) Biopharmaceutical Co1 program | Phase 3 once weekly, injection GLP-1 RA · CSPC Baike (Shandong) Biopharmaceutical Co | ||||||
| Eli Lilly8 programs | Phase 1 injection Class not reported · Eli Lilly | Phase 2 Dosing n/r Class not reported · Eli Lilly Registry, Dec 31, 2028 weekly, injection Myostatin/activin · Eli Lilly | Registry, Mar 14, 2027 once weekly, subcutaneous GIP/GLP-1/glucagon · Eli Lilly Registry, Mar 2028 once weekly, subcutaneous Amylin · Eli Lilly Phase 3 weekly, injection Class not reported · Eli Lilly | Registry, Jan 2027 once weekly, subcutaneous GLP-1/GIP · Eli Lilly Registry, Sep 6, 2027 once daily, tablet Oral small molecule · Eli Lilly | |||
| Empros Pharma AB1 program | Approved once monthly, oral Lipase inhibitor · Empros Pharma AB | ||||||
| Fujian Shengdi Pharmaceutical Co1 program | Registry, Oct 31, 2027 once weekly, oral and injection GLP-1/GIP · Fujian Shengdi Pharmaceutical Co | ||||||
| Gan & Lee Pharmaceuticals1 program | Registry, Jun 30, 2027 every 4 weeks, injection GLP-1 RA · Gan & Lee Pharmaceuticals | ||||||
| Gasherbrum Bio, Inc1 program | Phase 3 once daily, oral Oral small molecule · Gasherbrum Bio, Inc | ||||||
| GSK1 program | Phase 3 once weekly, oral and injection Class not reported · GSK | ||||||
| Guangdong Raynovent Biotech Co1 program | Phase 3 once weekly, oral and injection Class not reported · Guangdong Raynovent Biotech Co | ||||||
| Hangzhou Sciwind Biosciences Co1 program | Registry, Jan 5, 2027 once weekly, oral and injection GLP-1 RA · Hangzhou Sciwind Biosciences Co | ||||||
| Hanmi1 program | Phase 1 injection Class not reported · Hanmi | ||||||
| Hengrui1 program | Phase 3 once daily, oral and injection Class not reported · Hengrui | ||||||
| Huadong Medicine3 programs | Phase 3 once daily, oral GLP-1 RA · Huadong Medicine Phase 3 once weekly, injection Class not reported · Huadong Medicine Registry, Dec 2026 once weekly, injection GLP-1/GIP · Huadong Medicine | ||||||
| Innovent1 program | Registry, Dec 31, 2026 once weekly, oral and injection GLP-1 RA · Innovent | ||||||
| Inversago Pharma1 program | Phase 2 once daily, oral CB1 · Inversago Pharma | ||||||
| Merck1 program | Phase 1 oral and injection GLP-1/glucagon · Merck | ||||||
| MindRank AI Ltd1 program | Phase 3 oral Small molecule · MindRank AI Ltd | ||||||
| NeuroBo Pharmaceuticals Inc1 program | Registry, Nov 9, 2026 injection Class not reported · NeuroBo Pharmaceuticals Inc | ||||||
| NeuroSearch1 program | Phase 2 daily Monoamine reuptake · NeuroSearch | ||||||
| Novo Nordisk9 programs | Phase 2 once weekly, oral and injection Class not reported · Novo Nordisk Phase 2 once weekly, injection Class not reported · Novo Nordisk Phase 1/2 once monthly, oral and injection Serotonin agonist · Novo Nordisk | Registry, Jun 12, 2028 once weekly, oral and injection Class not reported · Novo Nordisk Registry, Feb 22, 2028 once daily, oral GLP-1 RA · Novo Nordisk Registry, Jan 26, 2027 once weekly, injection Amylin · Novo Nordisk | Registry, Mar 2027 once weekly, injection Amylin combo · Novo Nordisk | Registry, Sep 6, 2028 once weekly, injection and tablet GLP-1 RA · Novo Nordisk Approved once daily, oral and injection GLP-1 RA · Novo Nordisk | |||
| Orexigen Therapeutics, Inc1 program | Registry, Dec 31, 2030 daily Opioid and antidepressant · Orexigen Therapeutics, Inc | ||||||
| PegBio Co1 program | Phase 1/2 once weekly, injection Class not reported · PegBio Co | ||||||
| Pfizer5 programs | Phase 1 oral Oral small molecule · Pfizer | Phase 1/2 every 4 weeks, injection Class not reported · Pfizer Phase 2 once daily, oral Class not reported · Pfizer Phase 2 daily, oral and injection GLP-1 RA · Pfizer | Registry, Sep 21, 2027 once weekly, injection Class not reported · Pfizer | ||||
| Regeneron3 programs | Phase 2 injection Myostatin/activin · Regeneron Studied in NCT06299098 Dosing n/r Class not reported · Regeneron | Registry, Nov 13, 2026 once weekly, injection Class not reported · Regeneron | |||||
| Rhythm2 programs | Phase 2 daily, oral Class not reported · Rhythm | Registry, Mar 13, 2027 once daily, injection MC4R · Rhythm | |||||
| Roche3 programs | Registry, Oct 20, 2028 once weekly, injection Amylin · Roche Phase 3 once weekly GLP-1 RA · Roche Registry, Nov 12, 2027 once weekly, injection GLP-1/GIP · Roche | ||||||
| Sanofi3 programs | Phase 3 once daily, oral and injection GLP-1 RA · Sanofi Phase 3 once daily, oral CB1 · Sanofi Phase 3 once weekly, oral and injection Class not reported · Sanofi | ||||||
| Scholar Rock1 program | Phase 2 every 4 weeks, injection Myostatin/activin · Scholar Rock | ||||||
| Scohia1 program | IND submission Dosing n/r Class not reported · Scohia | ||||||
| Shandong Suncadia Medicine Co1 program | Phase 3 oral Oral small molecule · Shandong Suncadia Medicine Co | ||||||
| Shanghai Yinnuo Pharmaceutical Technology Co1 program | Registry, Nov 30, 2026 once weekly, injection GLP-1 RA · Shanghai Yinnuo Pharmaceutical Technology Co | ||||||
| Shanghai Yinnuo Pharmaceutical Technology Co.1 program | Phase 2/3 weekly, oral and injection GLP-1 RA · Shanghai Yinnuo Pharmaceutical Technology Co. | ||||||
| Shionogi1 program | Phase 2 once daily, oral Class not reported · Shionogi | ||||||
| Skye Bioscience1 program | Registry, Nov 20, 2026 injection Class not reported · Skye Bioscience | ||||||
| Terns, Inc1 program | Phase 2 once daily Oral small molecule · Terns, Inc | ||||||
| The United Bio-Technology (Hengqin) Co1 program | Registry, Jan 14, 2027 once weekly, oral and injection GIP/GLP-1/glucagon · The United Bio-Technology (Hengqin) Co | ||||||
| Verdiva Bio Dev Limited1 program | Phase 2 weekly, oral Class not reported · Verdiva Bio Dev Limited | ||||||
| Veru Inc1 program | Phase 2 weekly, oral and injection SARM · Veru Inc | ||||||
| Viking Therapeutics2 programs | Registry, Jul 2027 once weekly, subcutaneous GLP-1/GIP · Viking Therapeutics Phase 3 once daily, oral GLP-1/GIP · Viking Therapeutics | ||||||
| Vincentage Pharma Co1 program | Phase 3 once daily, oral Oral small molecule · Vincentage Pharma Co | ||||||
| VIVUS1 program | Phase 3 once daily, oral and injection Sympathomimetic combo · VIVUS | ||||||
| Zafgen1 program | Phase 3 weekly, injection MetAP2 inhibitor · Zafgen | ||||||
| Zealand Pharma1 program | Phase 2 once weekly, injection GLP-1 RA · Zealand Pharma |